GlassScriptPhysician profile
David Hernandez
NPI 1962817460
$1,133.02
in general payments reported to CMS, 2019-2025
12 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $91.55 · 2023: $145 · 2024: $531 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $272.86 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Astrazeneca Pharmaceuticals LP | $236.07 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $230.64 | 2021-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $113.73 | 2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $63.06 | 2022-2024 | |
| Amgen INC. | $48.67 | 2024 | Otezla, Repatha |
| Abbott Laboratories | $46.88 | 2022-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $38.23 | 2021-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.05 | 2024 | Xifaxan |
| Amarin Pharma, INC. | $21.06 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.94 | 2024 | Jardiance |
| Pfizer INC. | $13.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.